LMAO LMF ACQUISITION OPPORTUNITIES INC

SeaStar Medical to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21, 2023

SeaStar Medical to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21, 2023

DENVER, June 14, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Wednesday, June 21 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). Mr. Schlorff’s discussion will be hosted by Maxim Group Executive Managing Director of Research Anthony V. Vendetti.

Registration information to become a M-Vest member for access to the live and archived presentation webcast will be posted to section of the SeaStar Medical website.

About M-Vest

M-Vest is a division of Maxim Group LLC that serves to allow investors to access investment opportunities online and to provide a digital community built for issuers, investors, and thought leaders to share information. The platform provides insights on current market trends through presentations from innovative emerging growth companies and commentary from industry thought leaders via live events and Q&A.

About SeaStar Medical

SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

LHA Investor Relations

Jody Cain

(310) 691-7100

# # #



EN
14/06/2023

Underlying

LMAOLMF ACQUISITION OPPORTUNITIES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LMF ACQUISITION OPPORTUNITIES INC

 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical Announces $10 Million Registered Direct Offering Price...

SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules DENVER, July 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 947,868 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $10.55 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in...

July 10, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Pav...

SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has agreed to the final labeling for SeaStar Medical’s QUELIMMUNE™, the Selective Cytopheretic Device for pediatric patients, paving the way under t...

July 3, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presen...

SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that its patented, cell-directed, extracorporeal Selective Cytopheretic Device (SCD) is being featured in two presentations at the conference today, June 11, 2024. The International Vicenza Course – a scientific program that integrates ind...

June 11, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical Strengthens Board of Directors and Transitions to Comm...

SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected at the Company’s 2024 Annual Meeting of Stockholders held on June 4, and John Neuman was appointed to the Board on June 5. Former directors Bruce Rodgers and Richard Russell did not stand for reelection at the 2024 Annual Meeting, and Andres Lobo announced his retirement from Dow Ch...

June 10, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

Article in Nature Scientific Reports Describes Mechanism of Action of ...

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company’s Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. “,” ...

June 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch